Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Betta Pharmaceuticals Co.,Ltd.
ClinicalTrials.gov Identifier:
NCT01516983
First received: January 10, 2012
Last updated: February 13, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2013
  Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)